pancreatic cancer
Conditions
Interventions
Cohort 1, Experimental group (liposome irinotecan-based regimens (first-line therapy)):NA
Cohort 1, Control group (AG regimen (first-line therapy)):NA
Cohort 2 (liposome irinotecan-based regimens (second-line therapy)):NA
Sponsors
Fudan University Shanghai Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Patient is 18 years or older; 2.Histologically or cytologically proven pancreatic cancer; 3.Confirmed unresectable disease in a multidisciplinary consultation meeting; 4.Eastern Cooperative Oncology Group performance status score of 0~2; 5.Has a life expectancy of = 3 months; 6.Patient has signed informed consent and is willing to comply with the protocol.
Exclusion criteria
Exclusion criteria: 1.Complicated with uncontrollable systemic diseases (such as unstable angina pectoris, myocardial infarction, congestive heart failure, severe unstable ventricular arrhythmia, severe pericardial disease history, and other cardiovascular diseases; uncontrolled hypertension, diabetes, etc.); 2.Known allergies or intolerance to therapeutic drugs or their excipients; 3.Patients who are participating in other interventional clinical trials; 4.Have other malignant tumors requiring treatment; 5.Patient inappropriate for entry into this study judged by the Investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progress-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall response rate;Overall survival;Safety; | — |
Countries
China
Contacts
Public ContactXianjun Yu
Fudan University Shanghai Cancer Center
Outcome results
None listed